Phlegm dissolution via expectorant effect

Phlegm dissolution via expectorant effect refers to a therapeutic process aimed at facilitating the removal of mucus from the respiratory tract rather than a specific molecular target like a receptor or enzyme (StatPearls, 2023). This physiological outcome is achieved through various pharmacological mechanisms, including the hydration of airway surface liquid and the chemical degradation of mucin polymers (NIH, 2022). Expectorants, such as guaifenesin, typically increase the volume of secretions to make them easier to expel via coughing, whereas mucolytics like acetylcysteine reduce the viscosity of mucus by breaking disulfide bonds in glycoproteins (PubChem, 2024). These processes are critical in managing respiratory diseases characterized by mucus hypersecretion and impaired clearance, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and acute bronchitis (Mayo Clinic, 2023). Effective phlegm dissolution improves airway patency, reduces the work of breathing, and decreases the risk of secondary bacterial infections by preventing mucus stasis (Wikipedia, 2024).

Other names

Expectorant actionMucolysisAirway clearance enhancementMucociliary clearanceMucus thinning

Expectorants like guaifenesin increase the volume and reduce the viscosity of secretions in the trachea and bronchi by stimulating the vagal-gastric reflex or acting directly on bronchial glands (StatPearls, 2023). Mucolytics, such as acetylcysteine, chemically degrade mucus by breaking disulfide bonds between mucin polymers, thereby reducing the gel-like consistency of phlegm (PubMed, 2021). Other agents, like hypertonic saline, work osmotically to hydrate the airway surface liquid, while dornase alfa enzymatically cleaves extracellular DNA in the mucus of cystic fibrosis patients (NIH, 2022).